表紙
市場調査レポート

ナノメディシンの動向:技術ベンチマーキング&イノベーター分析

Trends in Nanomedicine - Technology Benchmarking & Innovator Analysis

発行 Technical Insights (Frost & Sullivan) 商品コード 348553
出版日 ページ情報 英文 108 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
ナノメディシンの動向:技術ベンチマーキング&イノベーター分析 Trends in Nanomedicine - Technology Benchmarking & Innovator Analysis
出版日: 2015年12月30日 ページ情報: 英文 108 Pages
概要

継続的な開発が続く新治療は、人口動態や公衆衛生への配慮に伴い注目に値すべきものとなっております。中でもナノテクノロジーはこの10年間で最も有力な実現技術であるとみなされてきました。

当レポートでは、ナノメディシンの動向について調査分析を行い、技術の概要と動向、産業モデル、用途、製品開発、市場の潜在性、主要企業、技術ベンチマーキングなどについて包括的に分析し、まとめています。

第1章 エグゼクティブサマリー

  • 調査の範囲
  • 調査方法
  • 主な調査結果

第2章 技術の概要と動向

  • 産業のバリューチェーンとビジネスモデル
  • 中核技術
  • 技術の進歩
  • 主な成長機会
  • 技術の相乗効果とナノバイオテクノロジー
  • 技術ロードマップ
  • 産業の促進因子と抑制因子
  • 産業の技術・ビジネスの課題
  • 市場の促進因子と抑制因子
  • 技術の促進因子と抑制因子
  • ファイブフォース分析

第3章 産業モデルとターゲット用途

  • ナノメディシン革新モデル
  • ナノメディシンの用途
  • ナノメディシンによる治療
  • ナノメディシンによる診断
  • ナノメディシンによる再生医療

第4章 製品の開発と市場の潜在性

  • マルチセグメンテーション
  • 主な産業の現実
  • 開発パイプライン
  • 製品:開発段階別
  • 世界市場
  • 製品パイプライン

第5章 主なステークホルダー分析

  • 上市製品
  • 北米の主要企業
  • 欧州の主要企業
  • アジア太平洋地域の主要企業
  • 知的財産

第6章 技術ベンチマーキング

  • 多基準アプローチ
  • 結論
  • 免責事項

第7章 付録

  • 主な連絡先

第8章 FROST & SULLIVANについて

目次
Product Code: D6C0-TI

Nano-based science paving the precision medicine era

The continued development of new treatments associated with the demographic trends and public health considerations is remarkable. Nanotechnology has been identified as one most relevant key enabling technologies of the last ten years, significantly impacting on many different biomedical developments in a broad spectrum of applications therapeutics, diagnostics, theranostics, medical imaging, regenerative medicine, life sciences research and biosciences, among many others. In fact, nanomedicine is present in all therapeutic areas, exhibiting a perceptible and extensive impact in the treatment and diagnosis of some most concerned diseases.

Innovation in nanomedicine fields has played a major role in the improvement of both length and quality of life during the present decade, appreciably advocated to reduce the disease burden for individuals and the society through completely new or improved diagnostic and therapeutic methods. Groundbreaking advances in the scientific understanding of the underlying mechanisms of disease are paving the way for nanomedicine on precision medicine topics.

Frost & Sullivan identified an unprecedented behavior in terms of innovation in nanomedicine fields, with notable acceptance in diagnostics, therapeutics, companion diagnostics, regenerative medicine, and many other applications that are undoubtedly linked to the concept of precision medicine. Nanomedicine enables personalized medicine approaches in many ways. As an instance, nano-based diagnostic tests or nano-imaging diagnosis may help to the stratification of patients and thereby to guarantee a most personalized, patient-centered therapy. In addition, clinical protocols become simpler, more efficient and less costly.

Table of Contents

1. EXECUTIVE SUMMARY

  • 1. Research Scope
  • 2. Research Scope (continued)
  • 3. Research Methodology
  • 4. Key Findings

2. TECHNOLOGY SNAPSHOT AND TRENDS

  • 1. Industry Value Chain and Business Model
  • 2. Core Technology Applications
  • 3. Technology Evolution
  • 4. Core Growth Opportunities
  • 5. Technology Synergy and Nanobiotechnology
  • 6. Technology Roadmap
  • 7. Industry Drivers and Restraints
  • 8. Industry Technical and Business Challenges
  • 9. Market Drivers and Restraints
  • 10. Technology Drivers and Restraints
  • 11. Porter's Five Forces Analysis

3. INDUSTRY MODELS AND APPLICATIONS TARGETED

  • 1. Nanomedicine Innovation Model
  • 2. Nanomedicine Innovation Model (continued)
  • 3. Nanomedicine Innovation Model (continued)
  • 4. Nanomedicines Application Focus
  • 5. Nanomedicines Therapeutics Focus
  • 6. Nanomedicines Diagnostics Focus
  • 7. Nanomedicines Regenerative Medicine Focus

4. PRODUCT DEVELOPMENT AND MARKET POTENTIAL

  • 1. Nanomedicine Multiple Segmentation
  • 2. Nanomedicines Principal Industry Facts
  • 3. Nanomedicines Principal Industry Facts (continued)
  • 4. Nanomedicine Development Pipeline
  • 5. Nanomedicine Products by Developmental Phase
  • 6. Global Nanomedicine Market
  • 7. Global Nanomedicine Market (continued)
  • 8. Global Nanomedicine Market (continued)
  • 9. Product Pipeline
  • 10. Product Pipeline (continued)
  • 11. Product Pipeline (continued)
  • 12. Product Pipeline (continued)
  • 13. Product Pipeline (continued)
  • 14. Product Pipeline (continued)

5. KEY STAKEHOLDER ANALYSIS

  • 1. Nanomedicine Marketed Products
  • 2. Nanomedicine Marketed Products (continued)
  • 3. Nanomedicine Marketed Products (continued)
  • 4. Key Companies in North America
  • 5. Key Companies in North America
  • 6. Key Companies in North America (continued)
  • 7. Key Companies in North America (continued)
  • 8. Key Companies in North America (continued)
  • 9. Key Companies in North America (continued)
  • 10. Key Companies in North America (continued)
  • 11. Key Companies in North America (continued)
  • 12. Key Companies in North America (continued)
  • 13. Key Companies in North America (continued)
  • 14. Key Companies in North America (continued)
  • 15. Key Companies in North America (continued)
  • 16. Key Companies in North America (continued)
  • 17. Key Companies in North America (continued)
  • 18. Key Companies in North America (continued)
  • 19. Key Companies in North America (continued)
  • 20. Key Companies in Europe
  • 21. Key Companies in Europe (continued)
  • 22. Key Companies in Europe (continued)
  • 23. Key Companies in Europe (continued)
  • 24. Key Companies in Europe (continued)
  • 25. Key Companies in Europe (continued)
  • 26. Key Companies in Europe (continued)
  • 27. Key Companies in Asia Pacific
  • 28. Key Companies in Asia Pacific (continued)
  • 29. Intellectual Property
  • 30. Intellectual Property (continued)
  • 31. Intellectual Property (continued)

6. TECHNOLOGY BENCHMARKING

  • 1. Multicriteria Approach for Benchmarking
  • 2. Multicriteria Approach for Benchmarking (continued)
  • 3. Multicriteria Approach for Benchmarking (continued)
  • 4. Multicriteria Approach for Benchmarking (continued)
  • 5. Multicriteria Approach for Benchmarking (continued)
  • 6. Multicriteria Approach for Benchmarking (continued)
  • 7. Multicriteria Approach for Benchmarking (continued)
  • 8. Multicriteria Approach for Benchmarking (continued)
  • 9. Multicriteria Approach for Benchmarking (continued)
  • 10. Final Remarks
  • 11. Legal Disclaimer

7. APPENDIX

  • 1. Key Contacts
  • 2. Key Contacts (continued)
  • 3. Key Contacts (continued)
  • 4. Key Contacts (continued)
  • 5. Key Contacts (continued)
  • 6. Key Contacts (continued)
  • 7. Key Contacts (continued)
  • 8. Intellectual Property Sources
  • 9. Key Patents
  • 10. Key Patents (continued)
  • 11. Key Patents (continued)

8. THE FROST & SULLIVAN STORY

  • 1. The Frost & Sullivan Story
  • 2. Value Proposition: Future of Your Company & Career
  • 3. Global Perspective
  • 4. Industry Convergence
  • 5. 360° Research Perspective
  • 6. Implementation Excellence
  • 7. Our Blue Ocean Strategy
Back to Top